Furthermore, recent progress in basic and translational research has improved treatment options for lymphoma, including FDA-approved crizotinib for ALK-positive ALCL and Brentuximab Vedotin for CD30-positive T-cell lymphoma [4, 5]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.